Is DSIP approved or legal?

No. DSIP is not approved as a drug by the FDA, EMA, or other major regulators. It is sold online as a research chemical for research use only, not for human consumption. Legality of possession varies by jurisdiction.

What dose is used and what is the half-life?

There is no validated clinical dose. Old human studies used intravenous DSIP in the microgram-per-kilogram range; community protocols cite roughly 100-300 mcg subcutaneously in the evening, but figures vary widely. The peptide is degraded very quickly (half-life on the order of minutes). This is reference information, not dosing advice.

Does DSIP actually improve sleep?

The evidence is weak and inconsistent. Early small studies reported sleep benefits, but they were largely uncontrolled and have not been reliably replicated, and the basic biology (receptor, pathway) remains unresolved. A major review called DSIP a 'still unresolved riddle.' Benefit cannot be considered proven.

Early clinical studies used intravenous injection; community use is typically subcutaneous (and sometimes intranasal). Because the peptide degrades rapidly and is unstable, real-world effects are unpredictable. No route has validated human dosing.

Human safety data are very limited and dated. Small early studies reported few serious adverse events, but there are no modern controlled or long-term safety studies, and unregulated, potentially degraded product quality is a real risk. It is not approved for human use and should be treated as a research compound.

Cognitive

DSIP

Also known as: Delta Sleep-Inducing Peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu

A naturally occurring nonapeptide originally linked to delta-wave sleep, with intriguing but inconsistent and poorly characterized evidence. Research use only.

Last updated July 11, 2026

Buy DSIP

Overview

DSIP (delta sleep-inducing peptide) is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated in 1977 by the Schoenenberger-Monnier group in Basel from the cerebral venous blood of rabbits during electrically induced slow-wave (delta) sleep. It was named for the early observation that infusing the peptide could increase delta-wave EEG activity in recipient animals, and it has since been studied for possible roles in sleep, stress regulation, pain, and modulation of various endocrine and autonomic functions. Despite nearly five decades of research, DSIP remains one of the more enigmatic neuropeptides: the gene, a definitive receptor, and a clear physiological pathway have not been firmly established, and findings across studies have been inconsistent. Some early small human studies reported benefits for insomnia, chronic pain, and withdrawal symptoms, but these were small, often uncontrolled, and have not been convincingly replicated in modern controlled trials. A frequently cited 2006 review described DSIP as a "still unresolved riddle." DSIP is not approved as a drug by the FDA, EMA, or other major regulators. It is sold online as a research chemical, typically labeled "for research use only." This entry summarizes the available science and community-reported practice for reference only; it is not medical advice and does not endorse human use.

How it works

DSIP's mechanism is not established. Despite its name, it does not have a confirmed, well-defined sleep-promoting pathway, and no specific DSIP receptor has been definitively identified. Proposed and partially supported actions include modulation of stress responses and the hypothalamic-pituitary-adrenal axis, interaction with or agonism at opioid-related systems (suggested by reports of effects on withdrawal symptoms), antioxidant activity, and influences on the release of several hormones. Some work suggests it acts more as a neuromodulator or stress-protective factor than as a direct hypnotic. Because the basic biology (gene, receptor, endogenous role) is still unresolved, all proposed mechanisms should be regarded as provisional and not validated in humans.

Researched effects

Preclinical Increased delta-wave (slow-wave) EEG activity in early animal infusion experiments
Clinical Improved sleep in small, mostly uncontrolled early human insomnia studies
Clinical Reduced pain in a small clinical pilot study of patients with chronic pain conditions
Clinical Eased alcohol and opiate withdrawal symptoms in an early clinical case series
Preclinical Stress-protective, antioxidant, and endocrine-modulating effects in animal/in-vitro models
Anecdotal Subjectively reported deeper or more restful sleep by community users

Evidence levels: Clinical (human trials) · Preclinical (animal/lab) · Anecdotal (community-reported).

Dosing reference

For research reference only — not a recommendation.

Clinical / studied dosing

No established or regulator-approved clinical dosing exists. Early small human studies used intravenous DSIP in the microgram-per-kilogram range (e.g., around 25 nmol/kg in a withdrawal-symptom series), typically as short courses of injections. These studies are old, small, and heterogeneous, and do not define a validated safe or effective dose. No modern controlled dose-finding trials have established a clinical protocol.

Community-reported dosing (anecdotal)

Anecdotal and research-reference only; not medical advice. Community sources and vendor guides commonly describe reconstituted subcutaneous DSIP at roughly 100-300 mcg taken in the evening before sleep, sometimes for short runs of a few weeks. Reported figures and timing vary widely and inconsistently between sources, reflecting a lack of standardization and the peptide's poor stability. These are unverified community practices, not tested safe or effective doses.

Half-life: Reported to be very short. DSIP is rapidly degraded by peptidases in blood and tissue, with sources citing a circulating half-life on the order of only a few minutes. This rapid breakdown is one reason its physiological role and any durable effects have been difficult to characterize; human pharmacokinetics are not well defined.
Routes: subcutaneous, intravenous, intranasal

Safety & side effects

Human safety data for DSIP are very limited and dated. The small early studies generally reported few serious adverse events at the doses tested, and as an endogenous peptide it is often assumed to have low acute toxicity, but there are no modern controlled safety or long-term studies. Reported or plausible issues include injection-site reactions and, given its rapid degradation, unpredictable real-world effects. Product quality is a major real-world risk: research-grade material is unregulated and may be impure, mislabeled, degraded, or contaminated, which is especially relevant for an unstable peptide. DSIP is not FDA/EMA-approved and is sold for research use only, not for human consumption. This information is for research reference only and is not a recommendation for human use.

Research summary

DSIP is a long-studied but still poorly understood neuropeptide. Since its 1977 isolation it has been investigated for sleep, stress, pain, and withdrawal, and early small human studies reported encouraging results, including normalized sleep in insomnia patients, reduced pain in a chronic-pain pilot, and relief of alcohol and opiate withdrawal symptoms. However, these studies were small, frequently uncontrolled or open-label, and were largely conducted decades ago without robust modern replication. The fundamental problem is that the basic biology remains unresolved. No DSIP gene, definitive receptor, or clear physiological pathway has been firmly established, the peptide is rapidly degraded in the body, and effects across studies have been inconsistent, leading a frequently cited 2006 review to call it a "still unresolved riddle." Even the central premise that DSIP reliably induces delta sleep is regarded by many researchers as weakly supported. The honest assessment is that DSIP is a scientifically interesting but unproven compound: its sleep and other benefits rest on old, limited, and unreplicated human data plus anecdote, its mechanism is speculative, and its stability and product-quality issues are significant. It should be treated as an experimental research compound, not a validated sleep aid, and claims of reliable benefit should be read with caution.

FAQ

Is DSIP approved or legal?: No. DSIP is not approved as a drug by the FDA, EMA, or other major regulators. It is sold online as a research chemical for research use only, not for human consumption. Legality of possession varies by jurisdiction.
What dose is used and what is the half-life?: There is no validated clinical dose. Old human studies used intravenous DSIP in the microgram-per-kilogram range; community protocols cite roughly 100-300 mcg subcutaneously in the evening, but figures vary widely. The peptide is degraded very quickly (half-life on the order of minutes). This is reference information, not dosing advice.
Does DSIP actually improve sleep?: The evidence is weak and inconsistent. Early small studies reported sleep benefits, but they were largely uncontrolled and have not been reliably replicated, and the basic biology (receptor, pathway) remains unresolved. A major review called DSIP a 'still unresolved riddle.' Benefit cannot be considered proven.
How is DSIP taken?: Early clinical studies used intravenous injection; community use is typically subcutaneous (and sometimes intranasal). Because the peptide degrades rapidly and is unstable, real-world effects are unpredictable. No route has validated human dosing.
Is DSIP safe?: Human safety data are very limited and dated. Small early studies reported few serious adverse events, but there are no modern controlled or long-term safety studies, and unregulated, potentially degraded product quality is a real risk. It is not approved for human use and should be treated as a research compound.

References

All content is for research and educational use only and is not medical advice. Products are sold for laboratory research only and are not for human consumption.